title: Clinical course and prognostic value of disease activity in the first two years in different subtypes of juvenile idiopathic arthritis.
abstract: OBJECTIVE
  Juvenile idiopathic arthritis (JIA) is a heterogeneous disease involving chronic arthritis. The clinical course is characterized by a fluctuating pattern of active and inactive disease. We have described in detail the clinical course in different JIA subtypes during the first 2 years after diagnosis and studied its relationship to disease activity in the following years.
  
  
  METHODS
  Detailed clinical data on different parameters describing the disease activity in sequential time periods covering the first 2 years after diagnosis were retrieved from the charts of 311 patients with JIA and compared between subtypes. In a cohort of 146 patients, the relation of these different clinical variables to the course of disease in the following 3 years was evaluated.
  
  
  RESULTS
  The percentage of time with active disease in the first 2 years differed significantly between subtypes. In all subtypes, a broad spectrum of activity was observed. The time with active disease in the first 2 years was the most significant factor associated with the duration of active disease in the following years.
  
  
  CONCLUSIONS
  Different percentages of time with active disease have been observed between JIA subtypes in the first 2 years. The cumulative duration of activity varied widely within each subtype. Regarding the prognosis of the individual patient, the clinical course in the first 2 years appears to be predictive of the clinical course in the following years. Patients that have less time with active disease in the first 2 years are not likely to develop an unremitting clinical course later on.
authors.affiliation: Leiden University Medical Centre, Leiden, The Netherlands.
authors.forename: H M
authors.initials: HM
authors.lastname: Albers
authors.forename: D M C
authors.initials: DM
authors.lastname: Brinkman
authors.forename: S S M
authors.initials: SS
authors.lastname: Kamphuis
authors.forename: L W A
authors.initials: LW
authors.lastname: van Suijlekom-Smit
authors.forename: M A J
authors.initials: MA
authors.lastname: van Rossum
authors.forename: E P A H
authors.initials: EP
authors.lastname: Hoppenreijs
authors.forename: H J
authors.initials: HJ
authors.lastname: Girschick
authors.forename: C
authors.initials: C
authors.lastname: Wouters
authors.forename: R K
authors.initials: RK
authors.lastname: Saurenmann
authors.forename: J J
authors.initials: JJ
authors.lastname: Houwing-Duistermaat
authors.forename: T W J
authors.initials: TW
authors.lastname: Huizinga
authors.forename: M W
authors.initials: MW
authors.lastname: Schilham
authors.forename: R
authors.initials: R
authors.lastname: ten Cate
mesh_terms: D000293:Adolescent; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001168:Arthritis / Q000503:physiopathology; D001171:Arthritis, Juvenile / Q000145:classification* / Q000188:drug therapy / Q000503:physiopathology*; D002648:Child; D002675:Child, Preschool; D015331:Cohort Studies; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D011237:Predictive Value of Tests; D011379:Prognosis; D012074:Remission Induction; D012189:Retrospective Studies; D013997:Time Factors
chemical_list: D018501:Antirheumatic Agents